Literature DB >> 7025339

Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.

O Matsuo, D C Rijken, D Collen.   

Abstract

The relative fibrinogenolytic, fibrinolytic and thrombolytic properties of human tissue plasminogen activator and human urokinase were compared in purified systems, in whole human plasma and in a system composed of a radioactive human blood clot (125I-fibrinogen) hanging in circulating human plasma. The human tissue plasminogen activator was highly purified from the culture fluid of a human melanoma cell line. In purified systems composed of fibrinogen of fibrin, plasminogen and alpha 2-antiplasmin as well as in whole plasma, tissue plasminogen activator digested fibrin without degrading fibrinogen significantly. Urokinase did not have this specific fibrinolytic effect. In the circulating plasma system, the degree of fibrinolysis was proportional to the amount of activator added, tissue plasminogen activator being about 10 times more efficient than urokinase. In addition, tissue plasminogen activator appeared to cause negligible fibrinogen degradation. Tissue plasminogen activator still induced significant thrombolysis at a concentration of 10 IU per ml whereas no effect of urokinase was observed at 20 IU per ml. Infusion of 100 IU (1 microgram) of tissue plasminogen activator per ml resulted in moderate activation of the fibrinolytic system as judged from a decrease of plasminogen and alpha 2-antiplasmin to 40-50 percent. Nevertheless, extensive fibrinolysis (50 to 80 percent of radioactivity released after 12 hrs) and only very limited fibrinogenolysis were observed. An equivalent amount of urokinase (100 IU per ml) only induced approximately 15 percent lysis in 12 hrs. At higher concentrations of urokinase (260 IU per ml or more) extensive activation of the fibrinolytic system was obtained as evidenced by a depletion of plasminogen, alpha 2-antiplasmin and fibrinogen. This was associated with extensive fibrinolysis (approximately 60 percent after 12 hrs). It is concluded that human tissue plasminogen activator is a more specific and effective fibrinolytic-thrombolytic agent than human urokinase.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7025339

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  19 in total

1.  Intravitreal recombinant tissue plasminogen activator in the treatment of experimentally induced bacterial endophthalmitis.

Authors:  N Baziuk; T Fang; G A Peyman; C M Gremillion
Journal:  Int Ophthalmol       Date:  1991-03       Impact factor: 2.031

2.  Thrombin-thrombomodulin inhibits prourokinase-mediated pleural mesothelial cell-dependent fibrinolysis.

Authors:  A V Iakhiaev; A Nalian; K Koenig; S Idell
Journal:  Thromb Res       Date:  2007-02-02       Impact factor: 3.944

3.  Synergistic fibrinolysis: combined effects of plasminogen activators and an antibody that inhibits alpha 2-antiplasmin.

Authors:  G L Reed; G R Matsueda; E Haber
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

4.  Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator.

Authors:  S Thorsen; S Müllertz; E Suenson; P Kok
Journal:  Biochem J       Date:  1984-10-01       Impact factor: 3.857

5.  Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence?

Authors:  J S Gelister; M R Lewin; H E Driver; F Savage; M Mahmoud; P J Gaffney; P B Boulos
Journal:  Gut       Date:  1987-07       Impact factor: 23.059

6.  Purified plasminogen activating factor produced by malignant lymphoid cells abrogates lymphocyte cytotoxicity.

Authors:  S K Sundar; J Bergeron; J Menezes
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

7.  Aspirin inhibits vascular plasminogen activator activity in vivo. Studies utilizing a new assay to quantify plasminogen activator activity.

Authors:  R I Levin; P C Harpel; D Weil; T S Chang; D B Rifkin
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

8.  Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis.

Authors:  C Korninger; O Matsuo; R Suy; J M Stassen; D Collen
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

Review 9.  Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.

Authors:  A J Wagstaff; J C Gillis; K L Goa
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

10.  Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.

Authors:  D Collen; J M Stassen; M Verstraete
Journal:  J Clin Invest       Date:  1983-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.